Gsk (GLAXF) EBITDA (2009 - 2026)

Gsk's EBITDA history runs 18 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, EBITDA rose 10.76% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $10.8 billion (up 17.65% YoY), while the FY2025 annual figure was $10.5 billion, up 103.47% from the prior year.
• EBITDA was $3.1 billion for Q1 2026 at Gsk, up from $1.5 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $5.2 billion in Q4 2023 to a low of $245.6 million in Q3 2024.
• Historically, EBITDA has averaged $2.6 billion across 5 years, with a median of $2.7 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 90.05% in 2024, then surged 1324.82% in 2025.
• A 5-year view of EBITDA shows it stood at $4.0 billion in 2022, then surged by 32.44% to $5.2 billion in 2023, then slipped by 23.21% to $4.0 billion in 2024, then tumbled by 63.65% to $1.5 billion in 2025, then surged by 111.28% to $3.1 billion in 2026.
• The last three EBITDA figures came in at $3.1 billion (Q1 2026), $1.5 billion (Q4 2025), and $3.5 billion (Q3 2025), per Business Quant data.